| Patient | Srinivasa Ramanujan |
|---|---|
| Date of birth | 1996-12-22 |
| Identifiers | MRN HR-ET020-SYN; SSN (made up) 000-20-1937 |
| Document date | 2026-11-01 |
| Author | Edmund Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient with four weeks of evening fevers and night sweats, weight loss and right upper quadrant pain, in a 29-year-old mathematician from Tamil Nadu who came to a research fellowship here three years ago. Concerns: He is afraid he has tuberculosis and wants to know what is wrong; He wants to keep working on his mathematics while he is treated; He wants any food and medicine advice to fit his diet and his tradition; He feels alone here and misses his family. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metronidazole 250 mg oral tablet, three tablets (750 mg) three times a day with food for 10 days | Three tablets every 8 hours with food for 10 days | Oral route | 2026-01-14 to 2026-01-23 | completed | S |
| Paromomycin 250 mg oral capsule, two capsules (500 mg) three times a day with meals for 7 days, started the day after metronidazole ends | Two capsules every 8 hours with meals for 7 days | Oral route | 2026-01-24 to 2026-01-30 | completed | S |
| Vitamin B12 (cyanocobalamin) 1,000 microgram oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-14 | active | S |
| Cholecalciferol 50,000 unit (1.25 mg) oral tablet, one tablet once a week for 8 weeks | One tablet once a week for 8 weeks | Oral route | 2026-01-14 to 2026-03-04 | completed | S |
| Cholecalciferol 2,000 unit (50 microgram) oral tablet, one tablet daily, from the end of the weekly course | One tablet daily | Oral route | 2026-03-05 | active | S |
| Rifampin 300 mg oral capsule, two capsules (600 mg) once daily on an empty stomach for 4 months | Two capsules each morning before breakfast for 4 months | Oral route | 2026-02-23 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest radiograph, two views | 2026-01-12 to 2026-01-12 | completed | S |
| Sputum induction with hypertonic saline for acid-fast smear, NAAT and mycobacterial culture (first of three samples) | 2026-01-12 to 2026-01-12 | completed | S |
| Ultrasound of the abdomen | 2026-01-13 to 2026-01-13 | completed | S |
| Advance care planning conversation, about 15 minutes | 2026-04-06 to 2026-04-06 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-04-06 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 2026-04-06 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-04-06 | Typhoid Vi capsular polysaccharide vaccine, injectable | completed | S |
| 2026-02-23 | Influenza vaccine, inactivated, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| December 1889 | Smallpox in early childhood; recovered | D (CLM-0003) |
| about 1906 | Dysentery in India, two episodes, the first about eleven years ago (dates approximate); no record of the treatment | D (CLM-0004) |
| 1909 | A serious illness followed by an operation, with a long recovery | D (CLM-0003) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He is afraid he has tuberculosis and wants to know what is wrong | active | S |
| He wants to keep working on his mathematics while he is treated | active | S |
| He wants any food and medicine advice to fit his diet and his tradition | active | S |
| He feels alone here and misses his family | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 7.4 on 2026-03-16; Hemoglobin [Mass/volume] in Blood 13.8 on 2026-04-20; MCV [Entitic mean volume] in Red Blood Cells by Automated count 90 on 2026-04-20; Platelets [#/volume] in Blood by Automated count 262 on 2026-04-20; C reactive protein [Mass/volume] in Serum or Plasma 11 on 2026-03-16; Sodium [Moles/volume] in Serum or Plasma 134 on 2026-01-12; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-01-12; Creatinine [Mass/volume] in Serum or Plasma 0.94 on 2026-01-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 113 on 2026-01-12; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 104 on 2026-03-16; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 32 on 2026-03-16; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-04-20; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 2026-04-20; Albumin [Mass/volume] in Serum or Plasma 3.9 on 2026-02-23; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-01-12; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 520 on 2026-04-20; Folate [Mass/volume] in Serum or Plasma 12.4 on 2026-01-12; Ferritin [Mass/volume] in Serum or Plasma 310 on 2026-01-12; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 32 on 2026-04-20; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-04-06; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 2026-04-20; Total score [AUDIT-C] 0 on 2026-04-06 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Evening fevers to 38.6 °C with night sweats for about four weeks | resolved | confirmed | R50.9 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Weight loss of 5 kg over two months (57 to 52 kg), with poor appetite | resolved | confirmed | R63.4 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Dull right upper quadrant pain for three weeks, worse on deep breathing and lying on the right side, with a tender liver edge | resolved | confirmed | R10.11 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Amebic liver abscess: a single 6.2 x 5.4 cm abscess in the right lobe (segment VII) on ultrasound, Entamoeba histolytica antibody positive, blood cultures negative, years after two episodes of dysentery in India; treated with metronidazole and then paromomycin; synthetic modern diagnosis linked to the hepatic amoebiasis later proposed for his illness | resolved | confirmed | A06.4 | S — Synthetic modern diagnosis; it does not settle the historical diagnostic conflict (CLM-0010, CLM-0011). |
| Vitamin B12 deficiency from a strict vegetarian diet (B12 168 pg/mL), with anemia (hemoglobin 11.2 g/dL, MCV 99 fL) to which inflammation also contributes | active | confirmed | D51.3 | S — Synthetic finding anchored to his documented diet and the vitamin deficiency later proposed. |
| Vitamin D deficiency (25-hydroxyvitamin D 9 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding anchored to his documented diet and the vitamin deficiency later proposed. |
| Positive interferon-gamma release assay, with chest radiograph and sputum smears and NAAT negative for tuberculosis; cultures pending | resolved | confirmed | R76.12 | S — Synthetic finding, superseded by the diagnosis of latent infection when cultures were negative. |
| Latent tuberculosis infection: positive interferon-gamma release assay, normal lungs on the radiograph, three sputum smears, NAAT and cultures negative; treated with four months of rifampin | active | confirmed | Z22.7 | S — Synthetic modern diagnosis; active tuberculosis was excluded, which does not settle the historical question. |
| Adjustment disorder with depressed mood (PHQ-9 12, no thoughts of self-harm) during a serious illness, far from his wife and family | active | confirmed | F43.21 | S — Synthetic modern diagnosis anchored to his documented loneliness; not a claim about his real mental health. |
| Acute viral upper respiratory infection, three weeks into rifampin and six weeks after treatment of the liver abscess, without signs of abscess relapse; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-12 | Leukocytes [#/volume] in Blood by Automated count | 13.6 | 10*3/uL | 4-11 10*3/uL | High | S |
| 2026-01-12 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-01-12 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 99 | fL | 80-100 fL | Normal | S |
| 2026-01-12 | Platelets [#/volume] in Blood by Automated count | 412 | 10*3/uL | 150-400 10*3/uL | High | S |
| 2026-01-12 | C reactive protein [Mass/volume] in Serum or Plasma | 92 | mg/L | <=5 mg/L | High | S |
| 2026-01-12 | Sodium [Moles/volume] in Serum or Plasma | 134 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-01-12 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 113 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-12 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 214 | U/L | 40-129 U/L | High | S |
| 2026-01-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 46 | U/L | 7-41 U/L | High | S |
| 2026-01-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 10-40 U/L | Normal | S |
| 2026-01-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-01-12 | Albumin [Mass/volume] in Serum or Plasma | 3.2 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal | Normal | S |
| 2026-01-12 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 168 | pg/mL | 232-1245 pg/mL | Low | S |
| 2026-01-12 | Folate [Mass/volume] in Serum or Plasma | 12.4 | ng/mL | >=3 ng/mL | Normal | S |
| 2026-01-12 | Ferritin [Mass/volume] in Serum or Plasma | 310 | ng/mL | 24-336 ng/mL | Normal | S |
| 2026-01-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 9 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-01-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 2026-01-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-01-26 | Leukocytes [#/volume] in Blood by Automated count | 8.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-01-26 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-01-26 | Platelets [#/volume] in Blood by Automated count | 380 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-01-26 | C reactive protein [Mass/volume] in Serum or Plasma | 24 | mg/L | <=5 mg/L | High | S |
| 2026-01-26 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 | U/L | 40-129 U/L | High | S |
| 2026-01-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 7-41 U/L | Normal | S |
| 2026-01-26 | Albumin [Mass/volume] in Serum or Plasma | 3.5 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-01-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 10 | {score} | S | ||
| 2026-01-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 2026-02-23 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-23 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-02-23 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 94 | fL | 80-100 fL | Normal | S |
| 2026-02-23 | Platelets [#/volume] in Blood by Automated count | 290 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-02-23 | C reactive protein [Mass/volume] in Serum or Plasma | 6 | mg/L | <=5 mg/L | High | S |
| 2026-02-23 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 118 | U/L | 40-129 U/L | Normal | S |
| 2026-02-23 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-41 U/L | Normal | S |
| 2026-02-23 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-40 U/L | Normal | S |
| 2026-02-23 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-23 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-23 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 410 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-02-23 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-04-20 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 13.8 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 | fL | 80-100 fL | Normal | S |
| 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-20 | C reactive protein [Mass/volume] in Serum or Plasma | 2 | mg/L | <=5 mg/L | Normal | S |
| 2026-04-20 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 40-129 U/L | Normal | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-41 U/L | Normal | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 10-40 U/L | Normal | S |
| 2026-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-20 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 520 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-04-20 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 32 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-04-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S | ||
| 2026-03-16 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-16 | C reactive protein [Mass/volume] in Serum or Plasma | 11 | mg/L | <=5 mg/L | High | S |
| 2026-03-16 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 104 | U/L | 40-129 U/L | Normal | S |
| 2026-03-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 7-41 U/L | Normal | S |
| 2026-03-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-04-06 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-04-06 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-12 | Body height | 165 | cm | S |
| 2026-01-12 | Body weight | 52 | kg | S |
| 2026-01-12 | Body mass index (BMI) [Ratio] | 19.1 | kg/m2 | S |
| 2026-01-12 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-01-12 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-01-12 | Heart rate | 104 | /min | S |
| 2026-01-12 | Respiratory rate | 18 | /min | S |
| 2026-01-12 | Body temperature | 38.4 | Cel | S |
| 2026-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-01-14 | Body height | 165 | cm | S |
| 2026-01-14 | Body weight | 51.8 | kg | S |
| 2026-01-14 | Body mass index (BMI) [Ratio] | 19 | kg/m2 | S |
| 2026-01-14 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-01-14 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-01-14 | Heart rate | 100 | /min | S |
| 2026-01-14 | Respiratory rate | 18 | /min | S |
| 2026-01-14 | Body temperature | 38.2 | Cel | S |
| 2026-01-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-01-26 | Body height | 165 | cm | S |
| 2026-01-26 | Body weight | 52.6 | kg | S |
| 2026-01-26 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-01-26 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-01-26 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-01-26 | Heart rate | 80 | /min | S |
| 2026-01-26 | Respiratory rate | 16 | /min | S |
| 2026-01-26 | Body temperature | 36.8 | Cel | S |
| 2026-01-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-02-23 | Body height | 165 | cm | S |
| 2026-02-23 | Body weight | 54.8 | kg | S |
| 2026-02-23 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 2026-02-23 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-02-23 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-02-23 | Heart rate | 74 | /min | S |
| 2026-02-23 | Respiratory rate | 14 | /min | S |
| 2026-02-23 | Body temperature | 36.6 | Cel | S |
| 2026-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-20 | Body height | 165 | cm | S |
| 2026-04-20 | Body weight | 56.6 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 20.8 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 70 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.6 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-16 | Body height | 165 | cm | S |
| 2026-03-16 | Body weight | 55.2 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 20.3 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 88 | /min | S |
| 2026-03-16 | Respiratory rate | 16 | /min | S |
| 2026-03-16 | Body temperature | 37.8 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-06 | Body height | 165 | cm | S |
| 2026-04-06 | Body weight | 56 | kg | S |
| 2026-04-06 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-04-06 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-04-06 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-06 | Heart rate | 70 | /min | S |
| 2026-04-06 | Respiratory rate | 14 | /min | S |
| 2026-04-06 | Body temperature | 36.6 | Cel | S |
| 2026-04-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-01-12 | New patient with four weeks of evening fevers and night sweats, weight loss and right upper quadrant pain, in a 29-year-old mathematician from Tamil Nadu who came to a research fellowship here three years ago | finished | S |
| 2026-01-14 | Results of the abdominal ultrasound, serology and tuberculosis tests, with an infectious diseases consultation, and start of treatment | finished | S |
| 2026-01-26 | Day 12: end of metronidazole and start of paromomycin, blood count, CRP and liver tests, mood and safety review | finished | S |
| 2026-02-23 | Six weeks: recovery, final sputum cultures, liver tests before rifampin, vitamin B12, mood, influenza vaccine | finished | S |
| 2026-04-20 | Three months: abscess treatment complete, rifampin month two, blood count, liver tests, vitamins, mood, and plans to visit home | finished | S |
| 2026-03-16 | Same-day sick visit for a cold with fever, and the question of an abscess relapse | finished | S |
| 2026-04-06 | Periodic adult preventive visit with pre-travel advice | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Infectious diseases consultation at the second visit for fever, weight loss and right upper quadrant pain in a young man from South India with a history of dysentery, to interpret the tuberculosis and amebiasis tests, the imaging, and the choice and order of treatment | completed | GL-ATS-TBDX-2017, GL-CDC-AMEBA | S |
| Tuberculosis evaluation before any antibiotic: chest radiograph, three induced sputum samples for acid-fast smear, NAAT and mycobacterial culture, an interferon-gamma release assay, and HIV testing; airborne precautions until three smears are negative | completed | GL-ATS-TBDX-2017, GL-ATS-TB-2016 | S |
| Liver and gut evaluation: abdominal ultrasound tomorrow morning, Entamoeba histolytica serology, stool antigen or PCR and microscopy, two sets of blood cultures, liver tests and CRP | completed | GL-CDC-AMEBA, GL-OFID-AMEBA-2018 | S |
| Nutrition: vitamin B12, folate, ferritin and 25-hydroxyvitamin D measured; weight at every visit; a dietitian visit to plan meals within his vegetarian diet and his rules | completed | GL-AND-VEG-2016, GL-CMID-2026 | S |
| Mood and safety: PHQ-9 and GAD-7 at intake and at least monthly while symptoms last; structured safety assessment and a written safety plan with the 988 Suicide & Crisis Lifeline; safety reviewed at every visit; short-term counseling with the university counseling service, at times he chooses | completed | GL-USPSTF-DEP-2023, GL-SUICIDE-2024, GL-CMID-2026 | S |
| Support far from home: the university's international student office and his department's graduate office about leave and deadlines while he is ill; a regular time to call his family; introductions, at his wish, to the local Tamil association and a Hindu temple community with shared meals; a letter for his fellowship about his illness | completed | GL-USPSTF-DEP-2023 | S |
| Acetaminophen for fever and pain, no more than 3 g a day; nothing else until the results are known | completed | GL-CDC-AMEBA | S |
| Cold: rest, fluids, warm salt-water gargles, honey in warm water and acetaminophen; continue rifampin; no antibiotic; return for fever over three days, right upper quadrant pain, or breathlessness | completed | GL-CDC-LTBI-2020 | S |
| As the infectious diseases physician advised: metronidazole 750 mg three times a day for 10 days, then paromomycin 500 mg three times a day for 7 days, not taken together; no aspiration unless fever persists after 72 hours, the abscess grows, or rupture threatens; a nurse phone check on the third day; no repeat imaging if he recovers | completed | GL-CDC-AMEBA, GL-OFID-AMEBA-2018 | S |
| Vitamin B12 1,000 micrograms by mouth daily and vitamin D 50,000 units weekly for 8 weeks, then 2,000 units daily; a dietitian plan within his rules: protein from dal, chickpeas, beans, milk, curd and paneer; dairy and fortified foods for B12; batch cooking once a day for two meals; easy foods such as curd rice and khichdi on tired days; an Indian grocery delivery | completed | GL-AND-VEG-2016, GL-CMID-2026 | S |
| Latent tuberculosis infection, once cultures were negative and the liver tests normal: rifampin 600 mg daily for 4 months, with a monthly clinical check for nausea, rash, jaundice and adherence; liver tests at baseline and at two months because of the recent liver disease; orange body fluids explained | completed | GL-CDC-LTBI-2020, GL-ATS-TBDX-2017 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A diagnosis within days, with tuberculosis either confirmed or excluded before any treatment that could hide it | 2026-02-23 | completed | Amebic liver abscess diagnosed at the second visit; active tuberculosis excluded by the radiograph, three smears, NAAT and cultures at six weeks | S |
| No fever, the abscess treated, and the luminal course completed | 2026-04-20 | completed | Afebrile by the third day of metronidazole; paromomycin completed; CRP and liver tests normal | S |
| Regain at least half of the lost weight within three months, on a diet that keeps his rules | 2026-04-20 | completed | 52.0 to 56.6 kg, nearly all the weight lost | S |
| Vitamin B12 and vitamin D in the normal range and the anemia resolved | 2026-04-20 | completed | B12 520 pg/mL; 25-hydroxyvitamin D 32 ng/mL; hemoglobin 13.8 g/dL | S |
| PHQ-9 below 10 with no thoughts of self-harm, and regular contact with people who matter to him | 2026-04-20 | completed | PHQ-9 12 to 5; weekly calls home and a weekly meal with others from his community | S |
| Complete four months of rifampin for latent tuberculosis infection | 2026-04-20 | active | Month two of four; no side effects; liver tests normal | S |
Structured synthetic safety assessment on 2026-01-12: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. He has no thoughts of suicide or self-harm now and has had none. Because he is ill, isolated, far from home and screening in the moderate range, his risk factors were reviewed with him privately and a written safety plan was made: his warning signs (not sleeping, not eating, not wanting to see anyone), what helps, who he can call, and the clinic number. The 988 Suicide & Crisis Lifeline was given and saved in his phone. Lethal-means counseling: no firearm; medicines dispensed in short supplies. Safety reviewed at every visit [S]